Initiation of clozapine therapy in a patient with preexisting leukopenia: a discussion of the rationale of current treatment options.
Clozapine remains the most effective agent for diminishing or eliminating psychotic symptoms in treatment-resistant patients. However, among such patients, a small percentage (<3.0%) develops clozapine-induced granulocytopenia (CIG). In spite of the fact that lithium and granulocyte colony stimulating factor (G-CSF) have been shown to reverse CIG, many such patients are consigned to treatment with antipsychotic agents that have failed in the past. Apparently, their physicians are not aware that these patients can be salvaged for ongoing clozapine treatment. We report the effectiveness of lithium in reversing CIG in a young man with preexisting mild granulocytopenia. The rapidity of onset of leukocyte depletion is discussed in light of previously hypothesized autoimmune mechanisms of CIG. This case dramatizes the importance of lithium (or G-CSF) augmentation in those patients to maintain clozapine treatment so that their neutropenia can be reversed, and they can continue to benefit from the unique antipsychotic qualities of clozapine.
Boshes
R A
RA
Department of Psychiatry, VAMC Brockton/West Roxbury, Dr. John C. Corrigan Mental Health Center, Harvard Medical School, Fall River, Massachusetts 02720, USA [corrected].
Manschreck
T C
TC
Desrosiers
J
J
Candela
S
S
Hanrahan-Boshes
M
M
D000328:Adult; D000380:Agranulocytosis / Q000139:chemically induced* / Q000188:drug therapy; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008094:Lithium / Q000627:therapeutic use; D008297:Male; D015985:Precipitating Factors
D014150:Antipsychotic Agents; D008094:Lithium; D003024:Clozapine